Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform. This phase marks the transition of VitaGuard™ from a technological breakthrough into what the Company believes will be a scalable oncology infrastructure, designed to displace high-cost legacy monitoring systems throughout Southeast Asia. Initial deployments are expected to commence in select Southeast Asian medical hubs during 2026. The Economic Imperative: Shattering the $3,000 Barrier
KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnostics Pte. Ltd. ("Fidelion") and Tongshu Biotechnology. With the closing of the agreements, BGLC has become a strategic shareholder in Fidelion Diagnostics and secured exclusive commercial rights for the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform across Southeast Asia (ASEAN) — positioning the Company for long-term growth as precision oncology adoption accelerates a
SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC" or the "Company"), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,000 Equity Purchase Agreement (the "Facility") with ARC Group International Ltd. ("ARC"), a global investment bank and the parent of ARC Group Securities, a FINRA registered broker dealer. The Company believes this facility will provide it with long-term, discretionary access to capital to advance its strategic initiatives, including the commercialization of the VitaGuard™ minimal residual disease (MRD) platform, the addition of contract deve
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit
SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)